INSULIN DETEMIR (Levemir®)

Clinical Indication

Comments

Patients should not be initiated on any Levemir® product as it is being discontinued, with stock anticipated to last until 31st December 2026.

In primary care follow the circulated SBAR to identify, review and switch patients to an alternative insulin. A widespread switch should not be initiated and alternative insulins will need to be chosen on an individual patient basis.

Date of classification

September 2025

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.